24/7 Market News Snapshot 13 January, 2025 – Fractyl Health, Inc. Common Stock (NASDAQ:GUTS)

January 13, 2025

DENVER, Colo., 13 January, 2025 (247marketnews.com) – (Nasdaq:GUTS) are discussed in this article.
Fractyl Health, Inc. (Nasdaq:GUTS) has recently experienced notable fluctuations in its stock performance, opening at $2.09 before retreating to $2.02, a decline of about 9.19%. The previous trading session ended at $1.85, indicating a volatile market reaction. A significant increase in trading volume, which reached 1.26 million shares, suggests that investor interest in Fractyl may have been fueled by recent developments. Observing the stock’s performance will be crucial, particularly as it faces pivotal support at $1.85 and resistance around $2.09, with traders keenly watching for any potential reversal signals.

In an encouraging development, Fractyl has reported promising initial outcomes from its REMAIN-1 pivotal study, which focuses on sustained weight maintenance after discontinuation of GLP-1 drugs. Early results from the REVEAL-1 cohort have revealed that the first participant achieved an impressive 15% total body weight loss following the Revita procedure. This outcome comes at a crucial time as there is a pressing need for effective alternatives to GLP-1 medications in the fight against obesity and type 2 diabetes (T2D).

The data indicates a significant response from patients and healthcare providers, highlighting the demand for innovative weight management strategies. Dr. Shailendra Singh, a prominent figure in bariatric endoscopy, has praised these initial results as they reaffirm the company’s dedication to sustainable solutions in metabolic health. CEO Harith Rajagopalan emphasized the objective to redefine treatment pathways for metabolic diseases, positioning the Revita procedure as a potential game-changer for long-term obesity management. The REMAIN-1 study, which has over 100 participants enrolled across multiple clinical sites, is set to provide further insights with mid-point data analysis expected in Q2 2025, pointing toward a commitment to advancing treatment options for millions facing the challenges of obesity and T2D.

Related news for (GUTS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.